Finoriq research workspace
Compass Therapeutics, Inc. (CMPX) Historical Metrics
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops. Review CMPX valuation ratios, fundamentals, and filing metrics on Finoriq.
Company Snapshot
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tumor vascularization. It also develops CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells; CTX-8371, a bispecific inhibitor that targets programmed cell death protein-1 (PD-1) and ligand PD-L1 checkpoint inhibitor antibodies; and CTX-10726, a bispecific antibody that targets PD-1 and VEFG-A. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
- Company
- Compass Therapeutics, Inc. (CMPX)
- Ticker
- CMPX
- Market Cap
- $366.5M
- Latest Price
- $2.035
- Industry
- Biotech & Pharma
Compass Therapeutics, Inc. (CMPX) Current Valuation Metrics
Static valuation preview for Compass Therapeutics, Inc. (CMPX). Market data retrieved 2026-07-09. Filing currency USD.
| Metric | Value | Source |
|---|---|---|
| Earnings YieldLatest TTM net income divided by market cap. | -16.5% | Net Income | TTM Q1 2026 |
| Operating Cash Flow YieldLatest TTM operating cash flow divided by market cap. | -12.8% | Operating Cash Flow | TTM Q1 2026 |
| Price / BookMarket cap divided by stockholders' equity. | 2.22x | Stockholders' Equity | Q1 2026 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.